Orchestra BioMed Holdings, Inc. (OBIO) intrinsic value & 10-year financials
Orchestra BioMed Holdings, Inc. (OBIO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 6 fiscal years revenue grew 111.6% a year to $33.5M, with an average return on invested capital of -134.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $5.45
- Market cap
- $260.2M
- Revenue (FY2025)
- $33.5M
- Revenue growth (6-yr CAGR)
- 111.6%
- ROIC (10-yr avg)
- -134.0%
- Free cash flow (FY2025)
- -$49.5M
OBIO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $33.5M | -$52.7M | -$1.11 | -$49.5M | -154.7% | -166.6% |
| FY2024 | $2.6M | -$61.0M | -$1.66 | -$50.8M | -2437.5% | -185.2% |
| FY2023 | $2.8M | -$49.1M | -$1.48 | -$46.2M | -1866.2% | -296.9% |
| FY2022 | $3.5M | -$2.7M | -$0.09 | -$2.2M | -87.2% | 50.3% |
| FY2021 | — | -$378.8K | -$0.01 | — | — | -71.6% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Orchestra BioMed Holdings, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Orchestra BioMed Holdings, Inc. has historically struggled to out-earn its cost of capital, averaging just -5.6% ROIC.
Orchestra BioMed Holdings, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Orchestra BioMed Holdings, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-36.87 per share.